Document is current
Any future updates will be listed below
-
Authors
Nakahara, Takeshi
Murota, Hiroyuki
Noto, Shinichi
Matsukawa, Miyuki https://orcid.org/0000-0003-2632-8808
Toda, Rikiya https://orcid.org/0009-0003-4517-9163
Konishi, Yasuhito https://orcid.org/0000-0002-2171-8519
Michikami, Daisaku
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical
- License Information
-
More Information
Article History
Received: 21 February 2025
Accepted: 25 April 2025
First Online: 16 May 2025
Declarations
:
: Takeshi Nakahara has received consulting fees and/or speaker honoraria from Mitsubishi Tanabe Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, Maruho, Sanofi, AbbVie, Eli Lilly Japan, Sun Pharma and Otsuka Pharmaceutical. Hiroyuki Murota has received consulting fees and/or speaker honoraria from Maruho Co., Ltd., Sanofi K.K., Pfizer Japan Inc., Torii Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., AbbVie GK, and Otsuka Pharmaceutical Co., Ltd. Shinichi Noto has received speaker honoraria from Otsuka Pharmaceutical. Miyuki Matsukawa, Rikiya Toda, Yasuhito Konishi, and Daisaku Michikami are employees of Otsuka Pharmaceutical Co., Ltd.
: This study was approved on October 21, 2022 by the Research Ethics Committee of Research and Development Division, Otsuka Pharmaceutical Co., Ltd. (approval no: 221013). The dataset used in this study was purchased from the DeSC. We have permission to use this database for the purposes of the research presented in this study. As we used secondary anonymized data, no individual-level informed consent was obtained. The survey was conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects in Japan and Declaration of Helsinki.
